Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Rani Therapeutics Holdings, Inc.RANI · Entity 6642 | Director · Chief Executive Officer | September 27, 2026 | September 29, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Rani Therapeutics Holdings, Inc.
Report date September 27, 2026 · Filed September 29, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class A Common StockSEC Table I · non-derivative | Direct | 461,808 |
Reported balance
After 2026-09-27 transaction · row 1
1 source rowRow 1 · 2026-09-27 · Tax withholding · Disposed 7,928 · Balance 461,808 F1: Represents shares withheld by and surrendered to the Issuer to satisfy tax withholding obligations in connection with the settlement and release of the restricted stock units. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents shares withheld by and surrendered to the Issuer to satisfy tax withholding obligations in connection with the settlement and release of the restricted stock units.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 27, 2026 Filed Sep 29, 2026 20:42 UTC | Rani Therapeutics Holdings, Inc. RANI · Entity 6642 | Tax withholdingClass A Common Stock | 7,928 | $0.76 | $6,018.94 |
DisclosureSEC source: 0001193125-26-407684 · ownership.xml · nonDerivative · entry 1 Imran Talat · CIK 0001869579 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 461,808 F1 · kind: Represents shares withheld by and surrendered to the Issuer to satisfy tax withholding obligations in connection with the settlement and release of the restricted stock units. Read SEC document |
| July 17, 2026 Filed Jul 21, 2026 22:29 UTC | Rani Therapeutics Holdings, Inc. RANI · Entity 6642 | PurchaseClass A Common Stock | 35,000 | $0.72 | $25,193.00 |
DisclosureSEC source: 0001869579-26-000007 · ownership.xml · nonDerivative · entry 1 Imran Talat · CIK 0001869579 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 469,736 F1 · balance_after: Includes 12,343 shares held by VH Moll, L.P. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein. Read SEC document |
| June 27, 2026 Filed Jul 21, 2026 22:25 UTC | Rani Therapeutics Holdings, Inc. RANI · Entity 6642 | Tax withholdingClass A Common Stock | 7,927 | $0.74 | $5,865.98 |
DisclosureSEC source: 0001869579-26-000006 · ownership.xml · nonDerivative · entry 7 Imran Talat · CIK 0001869579 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 434,736 F1 · date: This transaction is being reported late due to inadvertent administrative oversight. F4 · kind: Represents shares withheld by and surrendered to the Issuer to satisfy tax withholding obligations in connection with the settlement and release of the restricted stock units. F3 · balance_after: Includes 12,343 shares held by VH Moll, L.P. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein. Read SEC document |
| June 03, 2026 Filed Jun 5, 2026 22:14 UTC | Rani Therapeutics Holdings, Inc. RANI · Entity 6642 | GrantStock Option (Right to Buy) · Derivative | 3,800,000 | $0.00 Strike: $0.88 | $0.00 |
DisclosureSEC source: 0001869579-26-000003 · ownership.xml · derivative · entry 1 Imran Talat · CIK 0001869579 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,800,000 Underlying: Class A Common Stock · 3,800,000 shares Expires 2036-06-02 F1 · derivative.exercise_date: The shares subject to the option vest as follows: 1/48th of the shares subject to the option vest monthly over four years from April 1, 2026, subject to the Reporting Person's Continuous Service (as defined in the Company's 2021 Equity Incentive Plan) through each such vesting date. Read SEC document |
| March 27, 2026 Filed Jul 21, 2026 22:25 UTC | Rani Therapeutics Holdings, Inc. RANI · Entity 6642 | Tax withholdingClass A Common Stock | 9,099 | $0.81 | $7,370.19 |
DisclosureSEC source: 0001869579-26-000006 · ownership.xml · nonDerivative · entry 6 Imran Talat · CIK 0001869579 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 442,663 F1 · date: This transaction is being reported late due to inadvertent administrative oversight. F4 · kind: Represents shares withheld by and surrendered to the Issuer to satisfy tax withholding obligations in connection with the settlement and release of the restricted stock units. F3 · balance_after: Includes 12,343 shares held by VH Moll, L.P. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein. Read SEC document |
| March 22, 2026 Filed Jul 21, 2026 22:25 UTC | Rani Therapeutics Holdings, Inc. RANI · Entity 6642 | Tax withholdingClass A Common Stock | 8,916 | $1.13 | $10,075.08 |
DisclosureSEC source: 0001869579-26-000006 · ownership.xml · nonDerivative · entry 5 Imran Talat · CIK 0001869579 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 451,762 F1 · date: This transaction is being reported late due to inadvertent administrative oversight. F4 · kind: Represents shares withheld by and surrendered to the Issuer to satisfy tax withholding obligations in connection with the settlement and release of the restricted stock units. F3 · balance_after: Includes 12,343 shares held by VH Moll, L.P. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein. Read SEC document |
| December 27, 2025 Filed Jul 21, 2026 22:25 UTC | Rani Therapeutics Holdings, Inc. RANI · Entity 6642 | Tax withholdingClass A Common Stock | 7,906 | $1.40 | $11,068.40 |
DisclosureSEC source: 0001869579-26-000006 · ownership.xml · nonDerivative · entry 4 Imran Talat · CIK 0001869579 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 460,678 F1 · date: This transaction is being reported late due to inadvertent administrative oversight. F4 · kind: Represents shares withheld by and surrendered to the Issuer to satisfy tax withholding obligations in connection with the settlement and release of the restricted stock units. F3 · balance_after: Includes 12,343 shares held by VH Moll, L.P. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein. Read SEC document |
| September 27, 2025 Filed Jul 21, 2026 22:25 UTC | Rani Therapeutics Holdings, Inc. RANI · Entity 6642 | Tax withholdingClass A Common Stock | 9,077 | $0.48 | $4,356.96 |
DisclosureSEC source: 0001869579-26-000006 · ownership.xml · nonDerivative · entry 3 Imran Talat · CIK 0001869579 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 468,584 F1 · date: This transaction is being reported late due to inadvertent administrative oversight. F4 · kind: Represents shares withheld by and surrendered to the Issuer to satisfy tax withholding obligations in connection with the settlement and release of the restricted stock units. F3 · balance_after: Includes 12,343 shares held by VH Moll, L.P. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein. Read SEC document |
| June 27, 2025 Filed Jul 21, 2026 22:25 UTC | Rani Therapeutics Holdings, Inc. RANI · Entity 6642 | Tax withholdingClass A Common Stock | 9,076 | $0.55 | $4,991.80 |
DisclosureSEC source: 0001869579-26-000006 · ownership.xml · nonDerivative · entry 2 Imran Talat · CIK 0001869579 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 477,661 F1 · date: This transaction is being reported late due to inadvertent administrative oversight. F4 · kind: Represents shares withheld by and surrendered to the Issuer to satisfy tax withholding obligations in connection with the settlement and release of the restricted stock units. F3 · balance_after: Includes 12,343 shares held by VH Moll, L.P. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein. Read SEC document |
| May 23, 2025 Filed May 23, 2025 21:58 UTC | Rani Therapeutics Holdings, Inc. RANI · Entity 6642 | GrantStock Option (Right to Buy) · Derivative | 1,053,000 | $0.00 Strike: $0.62 | $0.00 |
DisclosureSEC source: 0000950170-25-077179 · ownership.xml · derivative · entry 1 Imran Talat · CIK 0001869579 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,053,000 Underlying: Class A Common Stock · 1,053,000 shares Expires 2035-05-22 F1 · derivative.exercise_date: The shares subject to the option vest as follows: 1/48th of the shares subject to the option vest monthly over four years from May 23, 2025. Read SEC document |
| December 27, 2024 Filed Jul 21, 2026 22:25 UTC | Rani Therapeutics Holdings, Inc. RANI · Entity 6642 | SaleClass A Common Stock | 8,014 | $1.41 | $11,299.74 |
DisclosureSEC source: 0001869579-26-000006 · ownership.xml · nonDerivative · entry 1 Imran Talat · CIK 0001869579 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 486,737 F1 · date: This transaction is being reported late due to inadvertent administrative oversight. F2 · kind: Represents the sale of shares to cover tax withholding obligations in connection with the settlement and release of the restricted stock units. F3 · balance_after: Includes 12,343 shares held by VH Moll, L.P. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein. Read SEC document |
| December 09, 2024 Filed Dec 10, 2024 18:12 UTC | Rani Therapeutics Holdings, Inc. RANI · Entity 6642 | PurchaseClass A Common Stock | 10,296 | $1.94 | $19,974.24 |
DisclosureSEC source: 0000950170-24-134828 · ownership.xml · nonDerivative · entry 1 Imran Talat · CIK 0001869579 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 494,751 F1 · balance_after: Includes 12,343 shares held by VH Moll, L.P. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein. Read SEC document |
| March 21, 2024 Filed Mar 23, 2024 01:00 UTC | Rani Therapeutics Holdings, Inc. RANI · Entity 6642 | GrantStock Option (Right to Buy) · Derivative | 1,085,000 | $0.00 Strike: $3.60 | $0.00 |
DisclosureSEC source: 0000950170-24-035573 · ownership.xml · derivative · entry 1 Imran Talat · CIK 0001869579 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,085,000 Underlying: Class A Common Stock · 1,085,000 shares Expires 2034-03-20 F1 · derivative.exercise_date: The shares subject to the option vest as follows: 1/48th of the shares subject to the option vest monthly over four years from March 21, 2024. Read SEC document |
| December 16, 2023 Filed Dec 19, 2023 21:05 UTC | Rani Therapeutics Holdings, Inc. RANI · Entity 6642 | GrantStock Option (Right to Buy) · Derivative | 31,252 | Not disclosed Strike: $2.84 | Not disclosed |
DisclosureSEC source: 0000950170-23-071472 · ownership.xml · derivative · entry 8 Imran Talat · CIK 0001869579 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 31,252 Underlying: Class A Common Stock · 31,252 shares Expires 2031-07-28 F3 · price: The transactions reported herein reflect a one-time stock option repricing (the "Option Repricing") effective on December 16, 2023 (the "Repricing Date"). Pursuant to the Option Repricing, the exercise price of the repriced options has been amended to reduce the exercise price to $2.84 per share, the closing price of the Issuer's Common Stock on the Repricing Date. There is no change to the expiration dates or the vesting schedule of the repriced options. F6 · derivative.exercise_date: The shares subject to the option vest as follows: 1/48th of the shares subject to the option vest monthly over four years from June 17, 2021. Read SEC document |
| December 16, 2023 Filed Dec 19, 2023 21:05 UTC | Rani Therapeutics Holdings, Inc. RANI · Entity 6642 | Disposition to issuerStock Option (Right to Buy) · Derivative | 31,252 | Not disclosed Strike: $9.44 | Not disclosed |
DisclosureSEC source: 0000950170-23-071472 · ownership.xml · derivative · entry 7 Imran Talat · CIK 0001869579 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 47,699 Underlying: Class A Common Stock · 31,252 shares Expires 2031-07-28 F3 · price: The transactions reported herein reflect a one-time stock option repricing (the "Option Repricing") effective on December 16, 2023 (the "Repricing Date"). Pursuant to the Option Repricing, the exercise price of the repriced options has been amended to reduce the exercise price to $2.84 per share, the closing price of the Issuer's Common Stock on the Repricing Date. There is no change to the expiration dates or the vesting schedule of the repriced options. F2 · derivative.exercise_date: The remaining shares subject to the option are fully vested and exercisable as of the Repricing Date. F6 · derivative.exercise_date: The shares subject to the option vest as follows: 1/48th of the shares subject to the option vest monthly over four years from June 17, 2021. Read SEC document |
| December 16, 2023 Filed Dec 19, 2023 21:05 UTC | Rani Therapeutics Holdings, Inc. RANI · Entity 6642 | Grant271875 · Derivative | 271,875 | Not disclosed Strike: $2.84 | Not disclosed |
DisclosureSEC source: 0000950170-23-071472 · ownership.xml · derivative · entry 6 Imran Talat · CIK 0001869579 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 271,875 Underlying: Class A Common Stock · 271,875 shares Expires 2031-09-08 F3 · price: The transactions reported herein reflect a one-time stock option repricing (the "Option Repricing") effective on December 16, 2023 (the "Repricing Date"). Pursuant to the Option Repricing, the exercise price of the repriced options has been amended to reduce the exercise price to $2.84 per share, the closing price of the Issuer's Common Stock on the Repricing Date. There is no change to the expiration dates or the vesting schedule of the repriced options. F5 · derivative.exercise_date: The shares subject to the option vest as follows: 25% of the shares subject to the option vests on June 14, 2022; and 1/48th of the shares subject to the option vest monthly over the remaining three years. Read SEC document |
| December 16, 2023 Filed Dec 19, 2023 21:05 UTC | Rani Therapeutics Holdings, Inc. RANI · Entity 6642 | Disposition to issuerStock Option (Right to Buy) · Derivative | 271,875 | Not disclosed Strike: $19.56 | Not disclosed |
DisclosureSEC source: 0000950170-23-071472 · ownership.xml · derivative · entry 5 Imran Talat · CIK 0001869579 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 453,125 Underlying: Class A Common Stock · 271,875 shares Expires 2031-09-08 F3 · price: The transactions reported herein reflect a one-time stock option repricing (the "Option Repricing") effective on December 16, 2023 (the "Repricing Date"). Pursuant to the Option Repricing, the exercise price of the repriced options has been amended to reduce the exercise price to $2.84 per share, the closing price of the Issuer's Common Stock on the Repricing Date. There is no change to the expiration dates or the vesting schedule of the repriced options. F2 · derivative.exercise_date: The remaining shares subject to the option are fully vested and exercisable as of the Repricing Date. F5 · derivative.exercise_date: The shares subject to the option vest as follows: 25% of the shares subject to the option vests on June 14, 2022; and 1/48th of the shares subject to the option vest monthly over the remaining three years. Read SEC document |
| December 16, 2023 Filed Dec 19, 2023 21:05 UTC | Rani Therapeutics Holdings, Inc. RANI · Entity 6642 | GrantStock Option (Right to Buy) · Derivative | 153,650 | Not disclosed Strike: $2.84 | Not disclosed |
DisclosureSEC source: 0000950170-23-071472 · ownership.xml · derivative · entry 4 Imran Talat · CIK 0001869579 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 153,650 Underlying: Class A Common Stock · 153,650 shares Expires 2032-03-21 F3 · price: The transactions reported herein reflect a one-time stock option repricing (the "Option Repricing") effective on December 16, 2023 (the "Repricing Date"). Pursuant to the Option Repricing, the exercise price of the repriced options has been amended to reduce the exercise price to $2.84 per share, the closing price of the Issuer's Common Stock on the Repricing Date. There is no change to the expiration dates or the vesting schedule of the repriced options. F4 · derivative.exercise_date: The shares subject to the option vest as follows: 1/48th of the shares subject to the option vest monthly over four years from March 22, 2022. Read SEC document |
| December 16, 2023 Filed Dec 19, 2023 21:05 UTC | Rani Therapeutics Holdings, Inc. RANI · Entity 6642 | Disposition to issuerStock Option (Right to Buy) · Derivative | 153,650 | Not disclosed Strike: $13.21 | Not disclosed |
DisclosureSEC source: 0000950170-23-071472 · ownership.xml · derivative · entry 3 Imran Talat · CIK 0001869579 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 109,750 Underlying: Class A Common Stock · 153,650 shares Expires 2032-03-21 F3 · price: The transactions reported herein reflect a one-time stock option repricing (the "Option Repricing") effective on December 16, 2023 (the "Repricing Date"). Pursuant to the Option Repricing, the exercise price of the repriced options has been amended to reduce the exercise price to $2.84 per share, the closing price of the Issuer's Common Stock on the Repricing Date. There is no change to the expiration dates or the vesting schedule of the repriced options. F2 · derivative.exercise_date: The remaining shares subject to the option are fully vested and exercisable as of the Repricing Date. F4 · derivative.exercise_date: The shares subject to the option vest as follows: 1/48th of the shares subject to the option vest monthly over four years from March 22, 2022. F2 · balance_after: The remaining shares subject to the option are fully vested and exercisable as of the Repricing Date. Read SEC document |
| December 16, 2023 Filed Dec 19, 2023 21:05 UTC | Rani Therapeutics Holdings, Inc. RANI · Entity 6642 | GrantStock Option (Right to Buy) · Derivative | 479,667 | Not disclosed Strike: $2.84 | Not disclosed |
DisclosureSEC source: 0000950170-23-071472 · ownership.xml · derivative · entry 2 Imran Talat · CIK 0001869579 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 479,667 Underlying: Class A Common Stock · 479,667 shares Expires 2033-03-26 F3 · price: The transactions reported herein reflect a one-time stock option repricing (the "Option Repricing") effective on December 16, 2023 (the "Repricing Date"). Pursuant to the Option Repricing, the exercise price of the repriced options has been amended to reduce the exercise price to $2.84 per share, the closing price of the Issuer's Common Stock on the Repricing Date. There is no change to the expiration dates or the vesting schedule of the repriced options. F1 · derivative.exercise_date: The shares subject to the option vest as follows: 1/48th of the shares subject to the option vest monthly over four years from March 27, 2023. Read SEC document |
| December 16, 2023 Filed Dec 19, 2023 21:05 UTC | Rani Therapeutics Holdings, Inc. RANI · Entity 6642 | Disposition to issuerStock Option (Right to Buy) · Derivative | 479,667 | Not disclosed Strike: $5.44 | Not disclosed |
DisclosureSEC source: 0000950170-23-071472 · ownership.xml · derivative · entry 1 Imran Talat · CIK 0001869579 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 95,933 Underlying: Class A Common Stock · 479,667 shares Expires 2033-03-26 F3 · price: The transactions reported herein reflect a one-time stock option repricing (the "Option Repricing") effective on December 16, 2023 (the "Repricing Date"). Pursuant to the Option Repricing, the exercise price of the repriced options has been amended to reduce the exercise price to $2.84 per share, the closing price of the Issuer's Common Stock on the Repricing Date. There is no change to the expiration dates or the vesting schedule of the repriced options. F1 · derivative.exercise_date: The shares subject to the option vest as follows: 1/48th of the shares subject to the option vest monthly over four years from March 27, 2023. F2 · derivative.exercise_date: The remaining shares subject to the option are fully vested and exercisable as of the Repricing Date. F2 · balance_after: The remaining shares subject to the option are fully vested and exercisable as of the Repricing Date. Read SEC document |
| December 06, 2023 Filed Dec 7, 2023 22:18 UTC | Rani Therapeutics Holdings, Inc. RANI · Entity 6642 | PurchaseClass A Common Stock | 10,000 | $2.27 | $22,700.00 |
DisclosureSEC source: 0000950170-23-068864 · ownership.xml · nonDerivative · entry 1 Imran Talat · CIK 0001869579 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 484,455 F1 · balance_after: Includes 12,343 shares held by VH Moll, L.P. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein. Read SEC document |
| December 04, 2023 Filed Dec 6, 2023 13:00 UTC | Rani Therapeutics Holdings, Inc. RANI · Entity 6642 | PurchaseClass A Common Stock | 5,000 | $2.57 | $12,850.00 |
DisclosureSEC source: 0000950170-23-068442 · ownership.xml · nonDerivative · entry 1 Imran Talat · CIK 0001869579 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 474,455 F1 · balance_after: Includes 12,343 shares held by VH Moll, L.P. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein. Read SEC document |
| November 29, 2023 Filed Dec 1, 2023 13:00 UTC | Rani Therapeutics Holdings, Inc. RANI · Entity 6642 | PurchaseClass A Common Stock | 20,000 | $2.05 | $41,000.00 |
DisclosureSEC source: 0000950170-23-067149 · ownership.xml · nonDerivative · entry 1 Imran Talat · CIK 0001869579 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 469,455 F1 · balance_after: Includes 12,343 shares held by VH Moll, L.P. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein. Read SEC document |
| November 07, 2023 Filed Nov 9, 2023 21:05 UTC | Rani Therapeutics Holdings, Inc. RANI · Entity 6642 | PurchaseClass A Common Stock | 2,500 | $2.01 | $5,025.00 |
DisclosureSEC source: 0000950170-23-062001 · ownership.xml · nonDerivative · entry 2 Imran Talat · CIK 0001869579 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 449,455 F1 · balance_after: Includes 12,343 shares held by VH Moll, L.P. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein. Read SEC document |
| November 07, 2023 Filed Nov 9, 2023 21:05 UTC | Rani Therapeutics Holdings, Inc. RANI · Entity 6642 | PurchaseClass A Common Stock | 2,500 | $1.98 | $4,950.00 |
DisclosureSEC source: 0000950170-23-062001 · ownership.xml · nonDerivative · entry 1 Imran Talat · CIK 0001869579 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 446,955 F1 · balance_after: Includes 12,343 shares held by VH Moll, L.P. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein. Read SEC document |
| March 27, 2023 Filed Mar 30, 2023 00:59 UTC | Rani Therapeutics Holdings, Inc. RANI · Entity 6642 | GrantStock Option (Right to Buy) · Derivative | 575,600 | $0.00 Strike: $5.44 | $0.00 |
DisclosureSEC source: 0001415889-23-005592 · form4-03302023_120352.xml · derivative · entry 2 Imran Talat · CIK 0001869579 · Director · CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 575,600 Underlying: Class A Common Stock · 575,600 shares Expires 2033-03-26 F3 · derivative.exercise_date: The shares subject to the option vest as follows: 1/48th of the shares subject to the option vest monthly over four years from March 27, 2023. Read SEC document |
| March 27, 2023 Filed Mar 30, 2023 00:59 UTC | Rani Therapeutics Holdings, Inc. RANI · Entity 6642 | GrantClass A Common Stock | 353,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-23-005592 · form4-03302023_120352.xml · nonDerivative · entry 1 Imran Talat · CIK 0001869579 · Director · CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 444,445 F1 · date: The shares subject to the restricted stock unit grant vest as follows: 1/16th of the RSUs shall vest quarterly over four years from March 27, 2023. F2 · balance_after: Includes 12,343 shares held by VH Moll, L.P. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein. Read SEC document |
| March 22, 2023 Filed Mar 24, 2023 20:05 UTC | Rani Therapeutics Holdings, Inc. RANI · Entity 6642 | Tax withholdingClass A Common Stock | 7,988 | $5.95 | $47,528.60 |
DisclosureSEC source: 0000899243-23-009585 · doc4.xml · nonDerivative · entry 1 Imran Talat · CIK 0001869579 · Director · CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 90,945 F1 · shares: Represents the number of shares withheld by and surrendered to the Issuer on March 22, 2023, to satisfy tax withholding obligations that arose in connection with the vesting of the restricted stock units granted to Mr. Imran on March 22, 2022. F2 · balance_after: Includes 12,343 shares held by VH Moll, L.P. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein. Read SEC document |
| March 22, 2022 Filed Mar 25, 2022 01:10 UTC | Rani Therapeutics Holdings, Inc. RANI · Entity 6642 | GrantStock Option (Right to Buy) · Derivative | 263,400 | $0.00 Strike: $13.21 | $0.00 |
DisclosureSEC source: 0001209191-22-021022 · doc4.xml · derivative · entry 2 Imran Talat · CIK 0001869579 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 263,400 Underlying: Class A Common Stock · 263,400 shares Expires 2032-03-21 F2 · derivative.exercise_date: The shares subject to the option vest as follows: 1/48th of the shares subject to the option vest monthly over four years from March 22, 2022. Read SEC document |
| March 22, 2022 Filed Mar 25, 2022 01:10 UTC | Rani Therapeutics Holdings, Inc. RANI · Entity 6642 | GrantClass A Common Stock | 86,600 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-021022 · doc4.xml · nonDerivative · entry 1 Imran Talat · CIK 0001869579 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 98,943 F1 · deemedExecutionDate: The shares subject to the restricted stock unit grant vest as follows: 25% of the RSUs shall vest yearly over four years from March 22, 2022. Read SEC document |
| February 03, 2022 Filed Feb 8, 2022 02:52 UTC | Rani Therapeutics Holdings, Inc. RANI · Entity 6642 | OtherClass A Common Stock | 12,343 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-007647 · doc4.xml · nonDerivative · entry 2 Imran Talat · CIK 0001869579 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 12,343 F3 · shares: VH Moll, L.P., is a limited partner of VH Rani, LP. VH Moll, L.P. therefore received 12,343 Class A Shares distributed by VH Rani, LP. and now owns those shares directly. The Reporting Person is a member of the general partner and disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein. F3 · ownership.nature: VH Moll, L.P., is a limited partner of VH Rani, LP. VH Moll, L.P. therefore received 12,343 Class A Shares distributed by VH Rani, LP. and now owns those shares directly. The Reporting Person is a member of the general partner and disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein. Read SEC document |
| February 03, 2022 Filed Feb 8, 2022 02:52 UTC | Rani Therapeutics Holdings, Inc. RANI · Entity 6642 | OtherClass A Common Stock | 827,467 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-007647 · doc4.xml · nonDerivative · entry 1 Imran Talat · CIK 0001869579 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 0 F1 · kind: Biologix Partners, LP and VH Rani, LP. distributed these shares to its limited partners on a pro rata basis, for no consideration. F2 · shares: Represents previously held 378,564 shares of Class A Common Stock of the Issuer ("Class A Shares") held by Biologix Partners, LP and 448,903 Class A Shares held by VH Rani, LP. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein. F2 · ownership.nature: Represents previously held 378,564 shares of Class A Common Stock of the Issuer ("Class A Shares") held by Biologix Partners, LP and 448,903 Class A Shares held by VH Rani, LP. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein. Read SEC document |
| September 09, 2021 Filed Sep 14, 2021 00:01 UTC | Rani Therapeutics Holdings, Inc. RANI · Entity 6642 | GrantStock Option (Right to Buy) · Derivative | 725,000 | $0.00 Strike: $19.56 | $0.00 |
DisclosureSEC source: 0001209191-21-055770 · doc4.xml · derivative · entry 1 Imran Talat · CIK 0001869579 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 725,000 Underlying: Class A Common Stock · 725,000 shares Expires 2031-09-09 F1 · derivative.exercise_date: The shares subject to the option vest as follows: 25% of the shares subject to the option vests on June 14, 2022; and 1/48th of the shares subject to the option vest monthly thereafter over the following three years. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.